Table 2.
Subgroup analysis of myeloid-derived suppressor cell and progression free survival or overall survival.
| Subgroup | No Studies |
No Patients |
Random/ Fixed Model |
PFS: pooled HR [95%CI] |
I²= | P Value | Random/ Fixed Model |
OS: pooled HR [95%CI] |
I²= | P-Value |
|---|---|---|---|---|---|---|---|---|---|---|
| Melanoma | 10 | 720 | Fixed | 1.66 [1.18, 2.33] | 24% | 0.003 | Random | 2.03 [1.46, 2.83] | 51% | < 0.001 |
| NSCLC | 3 | 207 | Random | 1.68 [0.90, 3.13] | 84% | 0.10 | Random | 1.85 [0.88, 3.90] | 82% | 0.11 |
| Cancer stage IV | 8 | 515 | Fixed | 2.66 [1.84, 3.86] | 0% | <0.001 | Random | 2.01 [1.39, 2.92] | 56% | < 0.001 |
| PD-1/PDL-1 | 8 | 428 | Random | 1.75 [1.15, 2.67] | 77% | 0.009 | Random | 2.04 [1.20, 3.48] | 84% | 0.009 |
| CTLA-4 | 5 | 359 | N/A | N/A | N/A | Random | 2.09 [1.34, 3.27] | 58% | 0.001 | |
| Study population >median (n=45) |
9 | 797 | Random | 1.48 [0.95, 2.30] | 79% | 0.09 | Random | 2.08 [1.28, 3.39] | 88% | 0.003 |
| Study population <Median (n=44) |
8 | 283 | Fixed | 2.56 [1.80, 3.65] | 0% | <0.001 | Random | 2.14 [1.38, 3.32] | 53% | < 0.001 |
| Cutoff method: Median |
9 | 446 | Fixed | 2.04 [1.60, 2.60] | 5% | <0.001 | Fixed | 2.60 [1.96, 3.46] | 0% | < 0.001 |
| Cutoff method: other • |
8 | 589 | Random | 1.44 [0.56, 3.71] | 92% | 0.45 | Random | 1.79 [1.13, 2.85] | 86% | 0.01 |
| Western countries | 16 | 903 | Random | 1.83 [1.21, 2.77] | 78% | 0.004 | Random | 2.08 [1.45, 2.99] | 83% | < 0.001 |
Overall survival (OS); progression free survival (PFS); Hazard ratio (HR); 95% Confidence interval (95% CI); [lower limit of 95% CI, upper limit of 95% CI];•including Data distribution, Log-Rank statistic, Cox regression; not applicable (N/A).